Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jaber Alkhabouri"'
Autor:
Bassem Yamout, Raed Alroughani, Jihad Inshasi, Samar Farouk, Fatema Abdulla, Namareq Y. Al-Jarki, Abdulla Alasmi, Sarmad Al Fahad, Jaber Alkhabouri, Khalid Al-Saffar, Beatrice Benedetti, Beatriz Canibano, Dirk Deleu, Ali Hassan, Pournamy Sarathchandran, Ahmed Shatila, Mohammad Abouelnaga, Mona Thakre, Miklos Szolics, Amir Boshra
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1321-1335 (2024)
Abstract Cladribine tablets (CladT), like alemtuzumab, acts as an immune reconstitution therapy. However, CladT is administered orally (alemtuzumab is given by infusion) and without the potential for serious side effects that limit the therapeutic us
Externí odkaz:
https://doaj.org/article/a456e8fecb904caa838b18d50372bc33
Autor:
Raed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, Jaber Alkhabouri, Taoufik Alsaadi, Abdullah Alsalti, Amir Boshra, Beatriz Canibano, Samar Farouk Ahmed, Ahmed Shatila
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 265-280 (2020)
Abstract Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is especially challenging for pregnant patients, as withdrawal of DMDs leave the patient at risk of increased disease activity. We, a group of experts in
Externí odkaz:
https://doaj.org/article/e92c0e9961294bd483537024e3f5aa9c
Autor:
Abdullah Al-Asmi, Samar Farouk Ahmed, Raed Alroughani, Amir Boshra, Jaber Alkhabouri, Ahmed Shatila, Jihad Inshasi, Abdullah Alsalti, Beatriz Canibano, Taoufik Alsaadi
Publikováno v:
Neurology and Therapy
Neurology and Therapy, Vol 9, Iss 2, Pp 265-280 (2020)
Neurology and Therapy, Vol 9, Iss 2, Pp 265-280 (2020)
Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is especially challenging for pregnant patients, as withdrawal of DMDs leave the patient at risk of increased disease activity. We, a group of experts in MS care f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f1d967163ea1558e1ee33f0a85185a1
https://doi.org/10.1007/s40120-020-00201-8
https://doi.org/10.1007/s40120-020-00201-8
Autor:
Raed Alroughani, Jihad Inshasi, Mona Al Khawajah, Samar Farouk Ahmed, Yaser Al Malik, Jaber Alkhabouri, Ahmed Shatila, Salman Aljarallah, Edward J Cupler, Shireen Al Qureshi, Mona Thakre, Heba Elhasin, Aly Ezzat, Sherif Roushdy
Publikováno v:
Multiple sclerosis journal - experimental, translational and clinical. 8(1)
Background The prevalence of multiple sclerosis (MS) is increasing in Gulf Cooperation Council (GCC) countries. Multiple sclerosis contributes to significant burden on patients and caregivers. The pharmacological treatment in MS involves treating acu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00574944fa225cca4ec3bae0ba9ecce4
https://pubmed.ncbi.nlm.nih.gov/35284088
https://pubmed.ncbi.nlm.nih.gov/35284088
Autor:
Ramachandiran Nandhagopal, Ibrahim Al-Zakwani, Arunodaya R. Gujjar, Mortadha Eltigani Elyas, Jaber Alkhabouri, Abdullah Al-Asmi, Abdullah Alsalti, Marwa Al-Senani
Publikováno v:
Multiple sclerosis and related disorders. 53
The prevalence of multiple sclerosis (MS) has been changing not only globally but also in individual countries. We aim to estimate the prevalence of MS in the Omani population over the period from 2006-2019 as well as the incidence between 2015-2018.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2114f85c71ab017d3f3cdfa58a3dfcd0
https://pubmed.ncbi.nlm.nih.gov/34087687
https://pubmed.ncbi.nlm.nih.gov/34087687